Trial Profile
Anti-donor alloreactivity-guided CNI minimization versus unguided standard triple therapy in living-donor kidney transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2021
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 13 Mar 2021 Status changed from recruiting to completed.
- 10 Mar 2016 New trial record